1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. 2 Shen L,Bai Y,Lin X,et al.Abstract CT184:First-Line(1L)nivolumab(NIVO)plus chemotherapy(chemo)versus chemo in patients(pts)with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma(GC/GEJC/EAC):CheckMate 649 Chinese subgroup analysis[J].Cancer Research,2021,81(13_Supplement):184. 3 Qi C,Qin Y,Liu D,et al.1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system[J].Ann Oncol,2021,32:S1040. 4 Gibbs ZA,Whitehurst AW.Emerging contributions of cancer/Testis antigens to neoplastic behaviors[J].Trends Cancer,2018,4(10):701-712. 5 Wu SC,Munger K.Role and clinical utility of cancer/Testis antigens in head and neck squamous cell carcinoma[J].Cancers(Basel),2021,13(22):5690. 6 Meng X,Sun X,Liu Z,et al.A novel era of cancer/testis antigen in cancer immunotherapy[J].Int Immunopharmacol,2021,98:107889. 7 Jin J,Tu J,Ren J,et al.Comprehensive analysis to identify MAGEA3 expression correlated with immune infiltrates and lymph node metastasis in gastric cancer[J].Front Oncol,2021,11:784925. 8 Hollingsworth RE,Jansen K.Turning the corner on therapeutic cancer vaccines[J].NPJ Vaccines,2019,4:7. 9 Yang J,Li ZH,Zhou JJ,et al.Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice[J].Chin J Cancer,2010,29(4):359-364. 10 Kruit WH,Suciu S,Dreno B et al.Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein:results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma[J].J Clin Oncol,2013,31(19):2413-2420. 11 Dreno B,Thompson JF,Smithers BM,et al.MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected,MAGE-A3-positive,stage III melanoma(DERMA):a double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet Oncol,2018,19(7):916-929. 12 Vansteenkiste J,Zielinski M,Linder A,et al.Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer:phase II randomized study results[J].J Clin Oncol,2013,31(19):2396-2403. 13 Lu YC,Parker LL,Lu T,et al.Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-Cell receptor targeting the cancer germline antigen MAGE-A3[J].J Clin Oncol,2017,35(29):3322-3329. 14 Lestari B,Utomo RY.CEP55 inhibitor:extensive computational approach defining a new target of cell cycle machinery agent[J].Adv Pharm Bull,2022,12(1):191-199. 15 Blumenschein GR,Devarakonda S,Johnson M,et al.Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+)advanced non-small cell lung cancer[J].J Immunother Cancer,2022,10(10):e003581. 16 Tian Y,Liang P,Zhang L,et al.High expression of MAGE-C1 gene in colorectal cancer is associated with its poor prognosis[J].J Gastrointest Oncol,2021,12(6):2872-2881. 17 Shires K,Wyk TV,Wienand K.The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients[J].Blood Res,2021,56(3):156-165. 18 Ren Y,Lv Y,Li T,et al.High expression of PLAC1 in colon cancer as a predictor of poor prognosis:A study based on TCGA data[J].Gene,2020,763:145072. 19 Chen R,Sheng C,Ma R et al.PLAC1 is an independent predictor of poor survival,and promotes cell proliferation and invasion in cervical cancer[J].Mol Med Rep,2021,24(5):800. 20 Pan Y,Yu Y,Wang X,et al.Tumor-associated macrophages in tumor immunity[J].Front Immunol,2020,11:583084. |